Children with disabilities https://proudlyyours.com/stmap_37iydmeb.html?imitrex.clobetasol.levitra acido tranexamico mecanismo de accion vademecum ** PROSENSA, $7.93, down 67 pct (1:17 p.m. ET) An experimental drug for Duchenne muscular dystrophy fromGlaxoSmithKline and Prosensa failed to meet its goal in alate-stage clinical trial, the companies said on Friday. Thedrug, drisapersen, did not show a statistically significantimprovement in the distance that patients could walk in sixminutes compared to a placebo in the Phase three test.